Impact of Duffy polymorphisms on parasite density in Brazilian Amazonian patients infected by Plasmodium vivax

• Main Authors: Rechfy K. Abou-Ali, Anamika Dhyani, Alexandre L. Terço, Diana M. Toro, Katiane S. Gomes, Lucianna C. Tezza, Monique A. Negreiros, Celiane S. Batista, Márcia K. S. Souza, Edalton C. B. Sanguino, Sérgio R. L. Albuquerque
• Format: Article
• Language: English
• Published: BMC 2019-08-01
• Series: Malaria Journal
• Subjects: Alleles Duffy; Plasmodium vivax; Parasite density
• Online Access: http://link.springer.com/article/10.1186/s12936-019-2918-4

Abstract Background The Duffy glycoprotein acts as the entry point for merozoites of Plasmodium vivax in the invasion of red blood cells. The host–parasite relationship has revealed new perspectives regarding the association between Duffy polymorphisms that can impact both the parasite density of this Plasmodium and the symptoms of this type of malaria. This study investigates the impact of Duffy polymorphisms on parasite density in patients infected with P. vivax in the Brazilian Amazon region. Methods Genotypes and Duffy polymorphism allele frequencies were compared in 287 patients with malaria, presenting low, medium and high density of P. vivax. The diagnosis of malaria was performed using a specialized team with a standardized clinical-laboratory method, while the Duffy genotyping was performed through the Bead Chip BioArray system. Both teams are reference services in Brazil. Results The FY*01 and FY*02 alleles were found in all three parasite density classes: low, medium and high, but when these alleles form genotypes with FY*02N.01 and FY*02W.01 alleles, they are found only in patients with low parasite density and low symptomatology. Another interesting finding found in this study is the presence of the genotype FY*02N.01/FY*02W.01 in one of the patients, presenting a very low parasite density and malaria considered subclinical, a genotype which had not been previously described in the literature. Conclusion The presence of FY*02N.01 and FY*02W.01 alleles may have an impact on the reduction of clinical manifestations in malaria, leading to the development of subclinical malaria, making the infected individual an undetected natural reservoir, which may hinder the eradication of malaria in the Amazon.